Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
(4) - EconoTimes)
SANTA BARBARA, Calif., March 11, 2016 -- Sientra, Inc. (NASDAQ:SIEN) (“Sientra”), a medical aesthetics company, today announced that it has granted a nonstatutory stock option under its Inducement Plan for 30,000 shares of Sientra common stock to Douglas M. Goodner, Sientra’s new Director of Strategic Programs pursuant to the terms of his employment agreement with Sientra. This award was approved by the Compensation Committee of Sientra’s board of directors and was granted as an inducement material to Mr. Goodner’s entering into employment with Sientra, pursuant to Rule 5635(b)(4) of the NASDAQ Listing Rules.
Mr. Goodner’s stock option was granted effective March 8, 2016 and has a ten year term and an exercise price equal to $7.93 per share, which was the closing trading price of Sientra’s common stock on the NASDAQ Global Select Market on the date of grant. Such stock option vests over the course of four years, with 25% of the shares subject to the option vesting on the one-year anniversary of the grant date and 1/48 of the shares subject to the option vesting monthly thereafter, subject to the new employee's continued service relationship with Sientra on each vesting date.
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company committed to making a difference in patients' lives by enhancing their body image, growing their self-esteem and restoring their confidence. The Company was founded to provide greater choice to board-certified plastic surgeons and patients in need of medical aesthetics products. The Company has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its breast implants and breast tissue expanders exclusively to board-certified and board-admissible plastic surgeons and tailors its customer service offerings to their specific needs. The Company also offers a range of other aesthetic and specialty products.
Contact Investor Contact: The Ruth Group Nick Laudico / Brandon Vazquez (646) 536-7030 / 7032 [email protected]
